MUC16 and ovarian carcinoma: However, due to its rather low sensitivity for early stages of ovarian cancer, CA-125 is not considered an appropriate screening tool [27], although a two-step screening model comprising CA-125 and transvaginal ultrasound has been proposed by the Normal Risk Ovarian Screening Study [29].